Case study: neuroleptic withdrawal dyskinesia exacerbated by ongoing stimulant treatment.
Risk factors for neuroleptic withdrawal dyskinesia in children have not been well studied. The authors present a case of a child who had been treated with a combination of neuroleptics and stimulants for nonpsychotic aggressive behavior. A severe withdrawal dyskinesia precipitated by neuroleptic tapering was ameliorated by discontinuation of the psycho-stimulant. Although stimulants have been reported to increase certain involuntary movement disorders, this is the first known report of psychostimulant exacerbation of withdrawal dyskinesia.
Connor
D F
DF
Department of Psychiatry, University of Massachusetts Medical Center, Worcester 01655, USA.
Benjamin
S
S
Ozbayrak
K R
KR
D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003913:Dextroamphetamine / Q000008:administration & dosage / Q000627:therapeutic use*; D004155:Diphenhydramine / Q000008:administration & dosage / Q000627:therapeutic use*; D005473:Fluoxetine / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000175:diagnosis / Q000188:drug therapy*; D009069:Movement Disorders / Q000209:etiology*; D010546:Perphenazine / Q000008:administration & dosage / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D013375:Substance Withdrawal Syndrome / Q000150:complications*; D014743:Videotape Recording
D014150:Antipsychotic Agents; D005473:Fluoxetine; D004155:Diphenhydramine; D010546:Perphenazine; D003913:Dextroamphetamine